Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.
Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
Language barriers may hinder access to cancer care before patients even encounter a physician, a new study suggests.
Patients with current or past cancer have a higher prevalence of acute myocardial infarction as the cause of chest pain than patients without cancer.
In a pan-cancer analysis, patients with pancreatic acinar cell carcinoma had the highest prevalence of BRCA2 germline pathogenic variants.
Adding tumor-treating fields therapy to standard treatment improves survival in patients with metastatic non-small cell lung cancer, a study suggests.